Drug intelligence / Profile preview

KRASG12D

Development stage: Preclinical
Lead developer: Vegen Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

KRASG12D is an investigational small molecule inhibitor being developed by Vegen Therapeutics. It is designed to selectively target the G12D mutation of the KRAS protein, a member of the RAS family of GTPases that acts as a molecular switch in cell signaling. The G12D mutation is a common oncogenic driver that keeps the KRAS protein in a constitutively active state, leading to uncontrolled cell growth and survival in various malignancies. This therapeutic candidate is specifically being developed for the treatment of pancreatic cancer (PANC) and colorectal cancer (CRC), where KRAS G12D mutations are particularly prevalent. The program is currently in the IND-enabling phase of development.

Other names: KRAS G12D inhibitor

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on KRASG12D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRASG12D.

Explore the full profile